We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Peregrine Awarded Grant Under IRS Section 48D for Qualifying Therapeutic Discovery Projects


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Peregrine Awarded Grant Under IRS Section 48D for Qualifying Therapeutic Discovery Projects"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 
Nearly all of this grant is available for immediate reimbursement and supports the following projects:

•    Bavituximab for the treatment of patients with second-line non-small cell lung cancer
•    Bavituximab for the treatment of patients with front-line non-small cell lung cancer
•    Bavituximab for the treatment of patients coinfected with hepatitis C virus (HCV)/HIV
•    Cotara® for the treatment of patients with glioblastoma multiforme (GBM)

"This award comes at an opportune time and will help further advance our clinical programs which have already shown clinical promise for addressing unmet medical needs in the treatment of cancer and viral infections," said Steven W. King, president and chief executive officer of Peregrine. "We are pleased to have been awarded the full available amount of this valuable non-dilutive funding for each of the four programs for which we applied."
Advertisement